Univar Solutions scientists developed a lidocaine cream built on starch, sorbitol, coconut oil, and beeswax that matched a commercial benchmark on viscosity, assay, and hydration.
|Articles|September 2, 2001
- Pharmaceutical Technology-09-02-2001
- Volume 25
- Issue 9
Replacing the Animal Component in SerumEvaluating Raw Materials for Inclusion in Optimized Hybridoma Media
With the scarcity of CGMP facilities spurring a production crisis, manufacturers need to optimize their processes and formulations for individual hybridoma cell lines and production systems.
Advertisement
Articles in this issue
about 25 years ago
Six Sigma Can Give Contractors a Quality Advantageabout 25 years ago
Industry Changes OTC Labels as Deadline Approachesabout 25 years ago
A Report of the PQRI Workshop on Blend Uniformityabout 25 years ago
Are You Ready for Global Manufacturing?about 25 years ago
Pharmaceutical Coverage and Costsabout 25 years ago
Outsourcing OutlookAdvertisement
Related to this article
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Ravi Kiran Kaja, PhD, USP, explains what harmonization of extractables and leachables standards looks like in practice.
Jaenisch, Muraru, and Pandey discuss new skills for QC and regulatory teams, plus patient trust, as new approach methodologies reshape pharma.
Nine duloxetine recalls since 2024 show why generic drug manufacturers need route-level nitrosamine risk assessment, not end-product testing alone.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Nitrosamine Problems and Industry Solutions: PharmTech Explained
2
Formulation and Evaluation of a Sustainable Analgesic Cream Utilizing Renewable Bio-Based Ingredients and Green Chemistry Design Principles
3
AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing
4
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
5